# US 2024/0182540 A1 · Chimeric apoptotic signal targeting lymphocytes (tim-4 castl) and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0182540 A1
- Document ID: US20240182540A1
- Status: Published application
- Kind: A1
- Application number: 18/511,817
- Filed: 2023-11-16
- Published: 2024-06-06
- Earliest claimed: 2022-11-16
- Applicants: Duke University
- Inventors: Peter Fecci; Daniel Wilkinson; Ethan Srinivasan
- Web page: https://patentgrep.com/patent/US20240182540A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/4226: {Epidermal growth factor [EGF]}
- A61K 40/4285: {Lipids; Lipoproteins}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2239/15: Non-antibody based
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/47: Brain; Nervous system
- A61K 2239/57: Skin; melanoma
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides recombinant TIM-4 fusion proteins comprising an extracellular domain of TIM-4 and at least one co-stimulatory domain. Also provided are cells comprising the fusion protein and methods of making and using the same.

## Claims

### Claim 1

A TIM-4 fusion protein comprising a TIM-4 extracellular domain and at least one co-stimulatory domain, wherein the TIM-4 extracellular domain comprises SEQ ID NO: 7 or a sequence having at least 95% identity to SEQ ID NO: 7.

### Claim 2 (depends on 1)

The TIM-4 fusion protein of claim 1, wherein the TIM-4 extracellular domain comprises SEQ ID NO: 8.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the co-stimulatory domain comprises CD3 co-stimulatory domain.

### Claim 4 (depends on 3)

The fusion protein of claim 3, wherein the co-stimulatory domain further comprises one or both of a co-stimulatory domain from CD28 and 4-1BB.

### Claim 5 (depends on 4)

The fusion protein of claim 4, wherein the fusion protein further comprises a signal sequence and a transmembrane domain.

### Claim 6 (depends on 5)

The fusion protein of claim 5, wherein the fusion protein comprises SEQ ID NO: 3 or a sequence having at least 95% identity to SEQ ID NO: 3.

### Claim 7 (depends on 5)

The fusion protein of claim 5, wherein the fusion protein comprises SEQ ID NO: 5 or a sequence having at least 95% identity to SEQ ID NO: 5.

### Claim 8 (depends on 1)

A construct comprising a polynucleotide sequence encoding the TIM-4 fusion protein of claim 1 operably linked to a promoter.

### Claim 9 (depends on 8)

The construct of claim 8, wherein the construct is included in a lentiviral, retroviral or AAV vector.

### Claim 10 (depends on 9)

A T cell comprising the construct of claim 9.

### Claim 11 (depends on 10)

The T cell of claim 10, further comprising a chimeric antigen receptor (CAR).

### Claim 12 (depends on 11)

The T cell of claim 11, wherein the CAR is specific for a tumor antigen.

### Claim 13 (depends on 12)

The T cell of claim 12, wherein the CAR comprises an extracellular domain comprising an antigen binding region which binds to both a wildtype EGFR and an EGFR VIII variant.

### Claim 14 (depends on 10)

A method of treating cancer in a subject, the method comprising administering a therapeutically effective amount of the T cell of claim 10 and a pharmaceutically acceptable excipient, carrier and/or diluent.

### Claim 15

The method 14, wherein the cancer is a PS-associated cancer.

### Claim 16 (depends on 14)

The method of claim 14, wherein the T cell is administered intratumorally.

### Claim 17 (depends on 14)

The method of claim 14, wherein the subject is administered radiation and/or chemotherapy prior to administration of the T cell.

### Claim 18 (depends on 14)

The method of claim 14, further comprising administering a T cell activating immunotherapy.

### Claim 19 (depends on 12)

A method of treating cancer, the method comprising administering a therapeutically effective amount of the T cell of claim 12 and a pharmaceutically acceptable excipient, carrier and/or diluent.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is an EGFR-associated cancer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the EGFR-associated cancer comprises a glioma, glioblastoma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma (DIPG), a brain metastases, head and neck, ovarian, cervical, bladder or esophageal cancer.

### Claim 22 (depends on 19)

The method of claim 19, wherein the T cell is administered intratumorally or systemically.

### Claim 23 (depends on 19)

The method of claim 19, wherein the subject is administered radiation and/or chemotherapy prior to administration of the T cell.

### Claim 24 (depends on 19)

The method of claim 19, further comprising administering a T cell activating immunotherapy.
